SARS-CoV-2 vaccine - Bharat Biotech/ExcellGene/University of Sydney
Alternative Names: Variant-proof Covid-19 vaccine - Bharat Biotech/ExcellGene/University of Sydney; Variant-proof SARS-CoV-2 vaccine - Bharat Biotech/ExcellGene/University of SydneyLatest Information Update: 30 Aug 2022
At a glance
- Originator Bharat Biotech; ExcellGene; University of Sydney
- Developer ExcellGene
- Class COVID-19 vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections